Meta-analysis of safety for low event-rate binomial trials

Research Synthesis Methods

Volumn 3, Issue 1, 2012, Pages 30-50

  Shuster, Jonathan J ^a   Guo, Jennifer D ^b   Skyler, Jay S ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

meta analysis; odds ratio; random effects; relative risk

Indexed keywords

EID: 84886748182     PISSN: None     EISSN: 17592887     Source Type: Journal    
DOI: 10.1002/jrsm.1039     Document Type: Article

References (49)

1. Abbate A, Biondi-Zoccai GG, Appleton DL, Erne P, Schoenenberger AW, Lipinski MJ, Agostoni P, Sheiban I, Vetrovec GW. 2008. Survival and cardiac remodeling benefits in patients undergoing late percutaneous coronary intervention of the infarct-related artery: evidence from a meta-analysis of randomized controlled trials. Journal of the American College of Cardiology 51: 956–964.
2. Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke, M, Devereaux PJ, Kleijnen J, Moher D. 2009 Jul 21. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339: b2700.
3. Bath PM, Gray LJ. 2005. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 330: 342–345.
4. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. 2006. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. Journal of the American College of Cardiology 48: 1319–1325.
5. Bellamy L, Casas JP, Hingorani AD, Williams D. 2009. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 373: 1773–1779.
6. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. 2009. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. Journal of the American Medical Association 301: 1909–1919.
7. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. 2009. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373(9674): 1532–1542.
8. Bonett DG. 2009. Meta-analytic interval estimation for standardized and unstandardized mean differences. Psychological Methods 14: 225–238.
9. Borenstein M, Hedges L, Higgins J, Rothstein H. 2009. Introduction to Meta-Analysis. Wiley Publication, Chichester, UK.
10. Borenstein M, Hedges L, Higgins J, Rothstein H. 2010. A basic introduction to fixed-effect and random-effects models for meta-analysis. Research Synthesis Methods 1: 97–111.
11. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. 2007. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statistics in Medicine 26: 53–77.
12. Brar SS, Leon MB, Stone GW, Mehran R, Moses JW, Brar SK, Dangas G. 2009 May 5. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. Journal of the American College of Cardiology 53: 1677–1689.
13. Burr D, Doss H. 2005. A Bayesian semiparametric model for random-effects meta- analysis. Journal of the American Statistical Association 100: 242–251.
14. Cai T, Parast L, Ryan L. 2010. Meta-analysis for rare events. Statistics in Medicine 29(20): 2078–2089.
15. Carpenter J, Rucker G, Schwarzer G. 2008. Comments on ‘Fixed vs. random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death’ by J. J. Shuster, L. S. Jones and D. A. Salmon. Statistics in Medicine 27: 3910–3912.
16. Collet JP, Montalescot G, Le May M, Borentain M, Gershlick A. 2006. Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. Journal of the American College of Cardiology 48: 1326–1335.
17. de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. 2005. Rate vs. rhythm control in patients with atrial fibrillation: a meta-analysis. Archives of Internal Medicine 165: 258–262.
18. De Ferrari GM, Sanzo A. 2009. T-wave alternans in risk stratification of patients with nonischemic dilated cardiomyopathy: can it help to better select candidates for ICD implantation? Heart Rhythm 6(3 Suppl): S29–S35.
19. De Luca G, Ucci G, Cassetti E, Marino P. 2009. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. Journal of the American College of Cardiology 53: 1668–1673.
20. DerSimonian R, Laird N. 1986. Meta-analysis in clinical trials. Controlled Clinical Trials 7(3): 177–188.
21. Diamond GA, Bax L, Kaul S. 2007. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Annals of Internal Medicine 147: 578–581.
22. Emerson JD, Hoaglin DC, Mosteller F. 1993. A comparison of procedures for combining risk differences in sets of 2 × 2 tables from clinical trials. Journal of the Italian Statistical Society 2: 269–290.
23. Emerson JD, Hoaglin DC, Mosteller F. 1996. Simple robust procedures for combining risk differences in sets of 2 × 2 tables. Statistics in Medicine 15: 1465–1488.
24. Higgins JPT, Green S (eds). 2011. Cochrane Handbook for Systematic Reviews for Interventions, Version 5.1.0. Wiley Publication, Chichester, UK.
25. Higgins JPT, Thompson SG, Spiegelhalter DJ. 2009. A re-evaluation of random-effects meta-analysis. J. Roy. Statistical Society, Series A 172: 137–159.
26. Home PD, Pocock SJ, Beck-Nielsen H, et al. 2009. RECORD study team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre,randomised, open-label trial. Lancet 373: 2125–2135.
27. Laird N, Fitzmaurice G, Xiao D. 2010. Comments on 'Empirical vs. natural weighting in random effects meta-analysis. Statistics in Medicine 29: 1266–1267.
28. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke, M, Devereaux PJ, Kleijnen J, Moher D. 2009. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of Internal Medicine 18;151(4): W65–W94.
29. Mottillo S, Filion KB, Bélisle P, Joseph L, Gervais A, O'Loughlin J, Paradis G, Pihl R, Pilote L, Rinfret S, Tremblay M, Eisenberg MJ. 2009. Behavioural interventions for smoking cessation: a meta-analysis of randomized controlled trials. European Heart Journal 30: 718–730.
30. Myung SK, McDonnell DD, Kazinets G, Seo HG, Moskowitz JM. 2009. Effects of Web-based and computer-based smoking cessation programs: meta-analysis of randomized controlled trials. Archives of Internal Medicine 169: 929–937. Erratum in: Arch Intern Med. 2009; 169:1194–1194.
31. Nissen SE, Wolski K. 2007 Jun 14. Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. The New England Journal of Medicine 356(24): 2457–2471.
32. Nissen SE, Wolski K. 2010. Rosiglitazone revisited: an updated meta-analysis for myocardial infarction and cardiovascular mortality. Archives of Internal Medicine 170(14): 1191–1201.
33. Piccini JP, Berger JS, O'Connor CM. 2009. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. European Heart Journal 30: 1245–1253.
34. Rucker G, Schwarzer G, Carpenter J, Olkin I. 2009. Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells. Statistics in Medicine 28: 721–738.
35. Rucker G, Schwarzer G, Carpenter J, Schumacher M. 2010. Natural weighting, is it natural? Statistics in Medicine 29: 2963–2965.
36. Senn S. 2010. Hans van Houwelingen and the art of summing up. Biometrical Journal 52: 85–94.
37. Serfling RJ. 1980. Approximation Theorems in Mathematical Statistics. John Wiley Publication, New York, 118–125.
38. Shuster JJ. 1982. Nonparametric optimality of the sample mean and sample variance. The American Statistician 36: 176–178.
39. Shuster JJ. 2010a. Empirical vs. natural weighting in random effects meta-analysis. Statistics in Medicine 29: 1259–1265.
40. Shuster JJ. 2010b. Reply to Rucker G, Schwarzer G, Carpenter J, Schumacher M. ‘Natural weighting, is it natural?’ Statistics in Medicine 29: 2965–2966.
41. Shuster JJ. 2011. Review: Cochrane handbook for systematic reviews for interventions, Version 5.1.0, published 3/2011. Julian P.T. Higgins and Sally Green, Editors. Research Synthesis Methods 2: 126–130.
42. Shuster JJ, Hatton RC, Hendeles L. Winterstein AG. 2010. Reply to Discussion of ‘Empirical vs. natural weighting in random effects meta-analysis’ Statistics in Medicine 29: 1272–1281.
43. Shuster JJ, Jones LS, Salmon DA. 2007. Fixed vs. random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death. Statistics in Medicine 26: 4375–4385.
44. Shuster JJ, Jones LS, Salmon DA. 2008. Rebuttal to Carpenter et al. Comments on ‘Fixed vs. random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death’. Statistics in Medicine 27: 3912–3914.
45. Stijnen T, Hamza TH, Ozdemir P. 2010. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Statistics in Medicine29: 3046–3067.
46. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC. 2009. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008; 336:645-51. Erratum in: BMJ 339: b29510–b2591.
47. Sweeting MJ, Sutton AJ, Lambert PC. 2004. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine 23: 1351–1375.
48. Van Houwelingen HC, Zwinderman KH, Stijnen T. 1993. A bivariate approach to meta-analysis. Statistics in Medicine 12: 2273–2284.
49. Verdecchia P, Angeli F, Cavallini C, Gattobigio R, Gentile G, Staessen JA, Reboldi G. 2009. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. European Heart Journal 30: 679–688.